Search
Close this search box.

Genomics supporting better IVF outcomes

Project team members Savana Biondic, Dr. Jeremy Grushcow and Dr. G. Adam Reeves in front of a microscope image of a research-donated embryo
Facebook
Twitter
Email
LinkedIn

Improving outcomes and increasing access for Canadian families-to-be

Around four million people use in vitro fertilization (IVF) every year, but only 34% of IVF cycles succeed. At least 85% of the time, the genetics of the embryo itself cause the high rate at which transferred embryos fail to implant or to carry to term. Despite its cost, roughly $20,000 per cycle, clinicians currently do not have the technology to perform comprehensive embryo genetic testing.

A new project, led by Jeremy Grushcow of Juniper Genomics and Dr. Sophie Petroloulos at the University of Montreal, aims to develop a comprehensive single-cell whole-genome sequencing-based genetic test for embryos to give IVF patients and clinicians as much certainty as possible that the first embryo they choose to transfer will be successful.

The project, called Whole genome embryo sequencing workflow for improved IVF outcomes, and run in partnership with Juniper Genomics, will deliver a scalable biopsy processing workflow for cell handling and sample preparation that delivers optimal sequencing results in a cost-effective manner. With close to $5.7 million, announced in May as part of a larger $41 million investment, the project has the potential to change transform IVF- improving outcomes and increasing access for Canadian patients.

Project team members Savana Biondic, Dr. Jeremy Grushcow and Dr. G. Adam Reeves in front of a microscope image of a research-donated embryo
L to R: Project team members Savana Biondic, Dr. Jeremy Grushcow and Dr. G. Adam Reeves in front of a microscope image of a research-donated embryo

ABOUT GAPP

The Genomic Applications Partnership Program (GAPP) supports industry-facing partnered research projects that address real-world challenges. Designed to accelerate the social and economic impact of genomics, GAPP provides the space for research, innovation and application to thrive collaboratively. GAPP projects address real-world challenges and opportunities through greater collaboration between genomics scientists and the users of genomics research. They aim to stimulate public- and private-sector investment in Canadian genomics technologies, advancing technology uptake in receptors and moving technologies across readiness levels. 

Quick facts

  • Genome Canada’s Genomic Applications Partnership Program (GAPP) is a flagship initiative that recently marked its 10th year and 100th funded project.
    • GAPP leverages world-leading expertise and diversified public-private partnerships to accelerate the adoption of genomics solutions to generate broad economic and societal benefits for Canada
  • Budget 2021 provided $400 million over six years, starting in 2021–22, to support the creation of the Canadian Genomics Strategy to drive further innovation in genomics through commercialization and adoption. This funding included $136.7 million over two years, starting in 2022–23, for programming delivered by Genome Canada to kick-start the new strategy and complement existing genomics research and innovation programming.
  • Since 2000, Genome Canada has leveraged $1.6 billion in federal investment into a total investment of $3.9 billion in R&D including co-funding, supported over 13,784 talented research trainees, and spun-out more than 120 new Canadian companies.

Media contact

Nicola Katz
Director, Communications
Genome Canada
Cell: 613-297-0267
nkatz@genomecanada.ca

Share

Facebook
Twitter
Email
LinkedIn